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α -­‐MSH,	  β-­‐MSH,	  γ-­‐MSH:	  α-­‐,	  β-­‐	  and	  γ-­‐melanocyte-­‐stimulating	  hormones	  	  
ACTH:	  Adrenocorticotrophin	  
AGRP:	  Agouti-­‐related	  protein	  
BSA:	  Bovine	  Serum	  Albumin	  
CLIP:	  Corticotrophin-­‐like	  intermediate	  peptide	  
CRH:	  corticotropin-­‐releasing	  hormone	  
DMSO:	  Dimethyl	  sulfoxide	  
HRP:	  Horseradish	  peroxidase	  
Hu:	  Human	  
IgG:	  Immunoglobulin	  G	  
LHA:	  Lateral	  Hypothalamic	  Area	  
LPH:	  β-­‐lipotropin	  	  
MC1,2,3,4,5R	  :	  Melanocortin	  receptor	  1,2,3,4,5	  
NPY:	  Neuropeptide	  Y	  
OPD:	  O-­‐phenylenediamine	  dichloride	  	  
PAGE:	  Polyacrylamide	  gel	  electrophoresis	  
PBS:	  Phosphate	  Buffered	  Saline	  
PBST:	  Phosphate	  Buffered	  Saline	  with	  Tween	  
PC:	  Proprotein	  Convertases	  
POMC:	  Proopiomelanocortin	  
PVN:	  Paraventricular	  nucleus	  
PYY	  :	  Peptide	  YY	  
SA:	  Strix	  aluco	  
SDS:	  Sodium	  Dodecyl	  Sulfate	  
TA:	  Tyto	  alba	  





Adam	  J.	  Saint-­‐Roch	  
4	  
II.	  INTRODUCTION	  
A.	  POMC	  STRUCTURE	  AND	  SYNTHESIS	  
In	  humans	  the	  proopiomelanocortin	  (POMC)	  gene	  is	  located	  on	  the	  short	  arm	  of	  the	  chromosome	  2	  at	  
the	  23.3	  position	  and	  encodes	  a	  39kDa	  peptide	  with	  241	  amino	  acids.	  This	  peptide	  is	  the	  precursor	  of	  
the	  proopiomelanocortin	  prohormone	  and	  it	  is	  produced	  in	  both	  the	  anterior	  and	  posterior	  lobes	  of	  the	  
pituitary,	  as	  well	  as	  the	  arcuate	  nucleus	  of	  the	  hypothalamus.	  	  	  
Maturation	  of	  POMC	  involves	  glycosylation,	  acetylation,	  and	  selective,	  sequential	  and	  tissue	  specific	  
processing	  events	  mediated	  by	  proprotein	  convertases	  PC-­‐1/3	  and	  PC-­‐2.	  Proteolytic	  cleavage	  of	  POMC	  
at	  9	  different	  locations	  produces	  a	  variety	  of	  hormones,	  including	  adrenocorticotrophin	  (ACTH),	  α-­‐,	  β-­‐	  
and	  γ-­‐melanocyte-­‐stimulating	  hormones	  (α-­‐MSH,	  β-­‐MSH,	  γ-­‐MSH),	  corticotrophin-­‐like	  intermediate	  
peptide	  (CLIP),	  β-­‐lipotropin	  (β-­‐LPH),	  and	  β-­‐endorphin	  (Fig.	  1.).	  
	  
B.	  PROPROTEIN	  CONVERTASES	  AND	  POMC	  
The	  basic	  proprotein	  convertases	  are	  a	  family	  of	  seven	  secretory	  serine	  proteases	  -­‐	  PC-­‐1/3,	  PC-­‐2,	  furin,	  
PC-­‐4,	  PACE4,	  PC-­‐5/6,	  PC-­‐7	  -­‐	  that	  cleave	  precursor	  proteins	  at	  highly	  conserved	  basic	  motifs.	  Unlike	  the	  
other	  members	  of	  basic	  PCs,	  PC-­‐1/3	  and	  PC-­‐2	  are	  active	  at	  very	  acidic	  pH,	  typically	  reached	  in	  the	  
secretory	  granules	  [1]. 
PC-­‐1/3	  and	  PC-­‐2	  are	  crucial	  for	  POMC	  maturation	  that	  gets	  processed	  by	  these	  enzymes	  at	  9	  different	  
sites	  (Fig.1).	  The	  cleavage	  at	  a	  given	  site	  is	  preferentially	  carried	  out	  by	  either	  PC-­‐1/3	  or	  PC-­‐2.	  In	  turn,	  the	  
differential	  processing	  of	  POMC	  depends	  on	  the	  convertase	  tissue	  distribution:	  PC-­‐1/3	  is	  mostly	  
expressed	  in	  the	  anterior	  pituitary	  in	  order	  to	  produce	  mostly	  corticotropic	  hormones	  (ACTH,	  β-­‐LPH)	  
while	  PC-­‐2	  is	  mainly	  expressed	  in	  the	  intermediate	  pituitary	  involved	  in	  melanotropic	  hormones	  (MSHs)	  
secretion.	  	  
Apart	  from	  the	  anterior	  lobe	  and	  the	  intermediate	  lobe	  of	  the	  pituitary,	  PC-­‐1/3	  and	  PC-­‐2	  are	  distributed	  
in	  several	  other	  tissues,	  including	  endocrine	  organs	  involved	  in	  food	  intake	  and	  energy	  homeostasis:	  PC-­‐
2	  is	  present	  in	  pancreatic	  α-­‐cells	  and	  is	  involved	  in	  the	  conversion	  of	  proglucagon	  to	  glucagon.	  PC-­‐1/3	  is	  
present	  in	  the	  intestinal	  L-­‐cells	  and	  converts	  proglucagon	  to	  glucagon-­‐like	  peptides	  [2,3].	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Figure	  1.	  Sequential	  proteolytic	  cleavage	  of	  the	  POMC	  precursor.	  The	  first	  step	  involves	  the	  cleavage	  of	  the	  signal	  
peptide	  on	  the	  N-­‐terminal	  end	  of	  the	  precursor.	  Steps	  1,2	  and	  3	  are	  mediated	  by	  PC-­‐1/3	  only,	  and	  happen	  early	  in	  
the	  proteolytic	  cleavage.	  Steps	  4	  and	  5	  are	  mediated	  by	  PC-­‐1/3	  and	  strongly	  enhanced	  by	  PC-­‐2.	  Steps	  6	  and	  7	  are	  
mediated	  by	  PC-­‐2	  and	  happen	  later	  in	  the	  processing	  of	  POMC.	  [4]	  
	  
C.	  IMPLICATIONS	  IN	  HUMAN	  DISEASES	  
The	  melanocortin	  system,	  and	  therefore	  POMC	  and	  all	  its	  cleavage	  products,	  is	  involved	  in	  a	  great	  
number	  of	  body	  functions	  such	  as	  pigmentation,	  steroïdogenesis,	  energy	  homeostasis,	  food	  intake,	  
analgesia,	  skin	  pigmentation,	  sexual	  function,	  inflammation,	  immunomodulation,	  temperature	  control,	  
cardiovascular	  regulation	  and	  neuromuscular	  regeneration	  [5].	  	  
The	  role	  of	  POMC	  in	  food	  intake	  is	  well	  described:	  POMC	  neurons	  present	  in	  the	  arcuate	  nucleus	  of	  the	  
hypothalamus	  are	  stimulated	  directly	  by	  leptin,	  serotonin	  and	  insulin	  and	  indirectly	  by	  PYY	  which	  inhibits	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the	  Agouti-­‐related	  protein/Neuropeptide	  Y	  (AGRP/NPY)	  neurons	  which	  have	  the	  opposite	  effect	  from	  
POMC	  on	  food	  intake.	  The	  activation	  of	  these	  POMC	  neurons	  creates	  an	  anorexigenic	  stimulus	  that	  
reduces	  food	  intake	  through	  the	  action	  of	  α-­‐MSH	  on	  melanocortin	  receptor	  4	  (MC4R)	  of	  corticotropin-­‐
releasing	  and	  melanin-­‐concentrating	  hormones	  of	  the	  PVN	  [6,	  7].	  In	  parallel,	  corticotropin-­‐releasing	  
hormone	  (CRH)	  produced	  in	  the	  paraventricular	  nucleus	  (PVN)	  and	  the	  lateral	  hypothalamic	  area	  (LHA)	  
in	  response	  to	  stress	  can	  also	  increase	  the	  production	  of	  POMC	  through	  direct	  synaptic	  contact	  within	  
the	  hypothalamus.	  
Most	  -­‐if	  not	  all-­‐	  of	  POMC	  functions	  are	  the	  consequence	  of	  the	  binding	  of	  these	  hormones	  and	  pro-­‐
hormones	  to	  the	  melanocortin	  receptors,	  and	  therefore	  the	  function	  depends	  on	  hormones	  relative	  
affinities	  to	  them	  (Tab.	  1).	  
	  
Receptor	   Effect	  on	   Agonists	   Primary	  function	  
MC1R	   Immune	  system,	  skin,	  and	  neuronal	  cells	   α-­‐MSH	  >=	  ACTH	  >	  β-­‐
MSH	  >	  γ-­‐MSH	  
	  
Pigmentation	  
MC2R	   Adrenal	  glands,	  skin,	  adipose	  tissue	  and	  
bone	  cells	  
ACTH	   Glucocorticoid	  
biosynthesis	  
MC3R	   Immune	  system,	  GI	  tract,	  heart,	  kidneys,	  
placenta	  and	  CNS	  
γ-­‐MSH	  >	  β-­‐MSH	  >ACTH>	  
α-­‐MSH	  
Energy	  	  homeostasis	  
MC4R	   CNS,	  heart,	  lung,	  kidneys,	  testis	   β-­‐MSH	  >	  α-­‐MSH	  >ACTH>	  
γ-­‐MSH	  
Energy	  homeostasis	  
MC5R	   Skin,	  adipose	  tissue,	  GI	  tract,	  spleen,	  
sexual	  organs,	  bone	  marrow	  





Table	  1.	  Summary	  of	  melanocortin	  receptors	  functions	  and	  their	  affinity	  to	  the	  different	  possible	  agonists	  
[8,9,10]	  
	  
Correct	  expression	  and	  proteolytic	  processing	  of	  POMC	  by	  PC-­‐1/3	  and	  PC-­‐2	  are	  crucial	  for	  normal	  
metabolic	  function	  and	  pigmentation.	  In	  human,	  recessive	  mutations	  of	  POMC	  and	  PC-­‐1/3,	  and	  
dominant	  mutation	  of	  Melanocortin-­‐4	  Receptor	  have	  been	  documented	  and	  associated	  with	  obesity	  [7].	  
POMC	  deficiency	  is	  characterized	  by	  severe	  obesity	  from	  the	  first	  month	  of	  life,	  associated	  with	  
congenital	  adrenal	  insufficiency,	  pale	  skin	  as	  well	  as	  red	  hair,	  hypocortisolism	  and	  low	  α-­‐MSH.	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Lack	  of	  functional	  PC-­‐1/3	  also	  due	  to	  a	  recessive	  genetic	  disorder	  leads	  to	  obesity	  from	  the	  first	  month	  
of	  life	  associated	  with	  gonadotropic	  and	  corticotropic	  insufficiency	  as	  well	  as	  hyperproinsulinaemia.	  	  
In	  humans,	  the	  receptor	  MC1R	  is	  highly	  polymorphic	  with	  specific	  genetic	  variants	  associated	  with	  hair	  
and	  skin	  pigmentation	  phenotypes	  [10].	  
	  
III.	  AIM	  OF	  THE	  PROJECT	  
The	  aim	  of	  the	  project	  is	  to	  biochemically	  characterize	  POMC	  variants	  of	  barn	  owl	  and	  humans.	  	  
Genotyping	  analysis	  of	  wild	  barn	  owls	  revealed	  the	  expression	  of	  a	  POMC	  variant	  characterized	  by	  the	  
insertion	  of	  poly-­‐serine	  (Ser)	  sequences	  of	  different	  length.	  Notably,	  the	  poly-­‐Ser	  inserts	  found	  in	  barn	  
owls	  resemble	  the	  Ser-­‐Ser-­‐Gly	  insertions	  found	  in	  human	  POMC	  associated	  with	  an	  elevated	  body	  mass	  
index	  [11].	  How	  exactly	  the	  polymorphism	  is	  related	  to	  the	  disease	  in	  human	  is	  not	  known.	  	  
In	  order	  to	  assess	  owl	  POMC	  cleavage	  into	  the	  melanocortin	  hormones,	  the	  PC-­‐1/3	  and	  PC-­‐2	  
orthologues	  have	  been	  used.	  This	  study	  will	  allow	  first	  insights	  into	  the	  molecular	  mechanisms	  of	  
differential	  processing	  and	  glycosylation	  of	  owl/human	  POMC	  variants.	  Considering	  the	  structural	  and	  
functional	  conservation	  of	  POMC	  among	  vertebrates,	  we	  expect	  that	  findings	  obtained	  from	  these	  
studies	  can	  be	  translated	  into	  a	  better	  understanding	  of	  the	  role	  of	  these	  factors	  in	  human	  physiology	  
and	  disease.	  
	  
Part	  1:	  Production	  and	  purification	  of	  the	  different	  POMCs	  and	  PCs	  
In	  the	  first	  part	  of	  the	  project,	  we	  produced	  and	  purified	  POMC	  of	  Tyto	  alba	  	  (TA-­‐POMC)	  containing	  
18Ser,	  Strix	  aluco	  (SA-­‐POMC)	  containing	  3Ser,	  and	  human	  (Hu-­‐POMC),	  as	  well	  Tyto	  alba	  PC-­‐1/3	  and	  PC-­‐
2.	  
	  
Protein	  production:	  Proteins	  were	  produced	  in	  mammalian	  HEK293	  cells	  at	  the	  EPFL	  platform	  directed	  
by	  Dr.	  Hacker.	  Plasmids	  of	  Hu-­‐POMC,	  SA-­‐POMC,	  and	  TA-­‐POMC	  were	  tagged	  with	  HA	  and	  V5	  epitope	  
whereas	  PC-­‐1/3	  and	  PC-­‐2	  were	  tagged	  with	  V5	  epitope.	  Plasmids	  encoding	  each	  protein	  were	  expanded	  
to	  final	  1.5mg	  which	  is	  the	  quantity	  required	  for	  0.5L	  production	  of	  conditioned	  media	  by	  cell	  
suspension.	  Identity	  of	  each	  plasmid	  has	  been	  confirmed	  by	  sequencing	  prior	  to	  providing	  them	  to	  the	  
EPFL	  platform.	  	  
	  
Protein	  purification:	  18	  Serine	  TA-­‐POMC,	  SA-­‐POMC,	  and	  Hu-­‐POMC	  were	  HA	  tagged	  at	  the	  N-­‐terminus	  
and	  V5	  tagged	  at	  the	  C-­‐terminus.	  Protein	  purification	  was	  attempted	  using	  anti-­‐HA	  and	  anti-­‐V5	  matrix	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columns.	  Briefly,	  equilibrated	  matrix	  was	  loaded	  with	  0.5L	  of	  conditioned	  supernatant.	  HA/V5-­‐tagged	  
POMC	  protein	  retained	  in	  the	  column	  was	  eluted	  using	  HA/V5	  peptide	  solution.	  Aliquots	  of	  eluates	  and	  
flowthrough	  were	  analyzed	  by	  coomassie	  gel	  to	  check	  for	  the	  efficiency	  of	  purification.	  
	  
Part	  2:	  PC-­‐1/3	  and	  PC-­‐2	  in	  vitro	  analyses	  and	  competition	  assay	  
In	  vitro	  analyses	  of	  non	  purified	  Tyto	  alba	  PC-­‐1/3	  and	  PC-­‐2:	  Optimal	  in	  vitro	  activity	  of	  TA-­‐PC-­‐1/3	  and	  TA-­‐
PC-­‐2	  was	  assessed	  using	  as	  substrate	  the	  synthetic	  fluorogenic	  peptide	  Pyr-­‐RTKR-­‐MCA	  in	  buffer	  solutions	  
of	  different	  pHs.	  The	  proteases	  cleave	  the	  peptide	  releasing	  the	  MCA	  moiety,	  which	  becomes	  
fluorescent,	  allowing	  the	  monitoring	  of	  the	  reaction	  of	  cleavage.	  Mouse	  PC-­‐1/3	  and	  PC-­‐2	  provided	  by	  
our	  collaborators	  were	  used	  as	  controls.	  
	  
Competition	  assay:	  To	  determine	  the	  affinity	  of	  each	  POMC	  protein	  for	  the	  cognate	  enzyme,	  TA-­‐POMC,	  
SA-­‐POMC	  and	  Hu-­‐POMC	  were	  pre-­‐incubated	  with	  each	  proprotein	  convertase	  PC-­‐1/3	  and	  PC-­‐2,	  prior	  to	  
addition	  of	  the	  fluorogenic	  substrate.	  POMC-­‐fluorogenic	  substrate	  competition	  was	  monitored	  in	  vitro	  
as	  release	  of	  fluorescence/time.	  	  	  	  	  
	  
Part	  3:	  Testing	  of	  the	  custom	  anti-­‐POMC	  antibodies	  
Non-­‐purified	  POMC	  was	  used	  to	  assess	  the	  specificity	  of	  custom	  antibodies	  generated	  against	  TA-­‐POMC	  
and	  SA-­‐POMC	  using	  the	  enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  and	  western	  blotting	  (WB).	  Briefly,	  
supernatants	  from	  POMC	  over-­‐expressing	  cells	  were	  immobilized	  on	  a	  96	  well	  plate.	  Primary	  antibodies	  
(custom	  antibodies)	  were	  used	  in	  serial	  dilutions,	  followed	  by	  Horseradish	  peroxidase-­‐linked	  (HRP)	  
secondary	  antibodies.	  Upon	  addition	  of	  O-­‐phenylenediamine	  dichloride	  (OPD),	  reagent	  detection	  was	  
performed	  by	  measuring	  absorbance	  at	  450nm.	  Western	  blot	  analysis	  was	  performed	  as	  described	  
below.	  
	  
Part	  4:	  Purification	  of	  POMC	  using	  custom	  antibodies	  
Custom	  antibodies	  were	  selected	  according	  to	  their	  specificity	  against	  the	  different	  POMCs	  to	  purify	  SA-­‐
POMC	  with	  better	  efficiency	  than	  with	  the	  anti-­‐HA	  and	  anti-­‐V5	  matrix	  columns.	  This	  second	  attempt	  of	  
purification	  used	  magnetic	  Dynabeads	  coated	  with	  the	  custom	  antibody	  and	  compared	  to	  input	  samples	  
through	  western	  blot	  analysis.	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IV.	  MATERIAL	  AND	  METHODS	  
A.	  LIBRARY	  OF	  ANTIBODIES	  AGAINST	  POMC	  	  	  	  
The	  library	  contains	  27	  different	  antibodies	  targeting	  ACTH,	  γ-­‐MSH	  or	  β-­‐MSH.	  Antibodies	  are	  of	  diverse	  
origin	  (custom	  made	  or	  commercially	  available)	  and	  stored	  at	  -­‐20C	  for	  >	  2years.	  All	  antibodies	  have	  been	  










Peptide	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   Human	  
	  
Santa	  Cruz	  SC-­‐


























1-­‐ACTH-­‐1E3-­‐4-­‐1	   hybridoma	  
supernatant	  
mouse	   GRKRRPIKVYPNGVC	  (PJ	  126)	  
1-­‐ACTH-­‐2G9-­‐4-­‐1	   hybridoma	  
supernatant	  
mouse	   GRKRRPIKVYPNGVC	  (PJ	  126)	  
β-­‐MSH	   Tyto	  alba	   1-­‐MSH-­‐2B1-­‐1-­‐1	   hybridoma	  
supernatant	  
mouse	   SHRVRPFRWHAPLKDC	  (PJ	  
127)	  
1-­‐MSH-­‐3A1-­‐1-­‐1	   hybridoma	  
supernatant	  
mouse	   SHRVRPFRWHAPLKDC	  (PJ	  
127)	  
1-­‐MSH-­‐3B1-­‐1-­‐1	   hybridoma	  
supernatant	  
mouse	   SHRVRPFRWHAPLKDC	  (PJ	  
127)	  
1-­‐MSH-­‐3C12-­‐1-­‐1	   hybridoma	  
supernatant	  
mouse	   SHRVRPFRWHAPLKDC	  (PJ	  
127)	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1-­‐MSH-­‐3F2-­‐1-­‐4	   hybridoma	  
supernatant	  
mouse	   SHRVRPFRWHAPLKDC	  (PJ	  
127)	  
1-­‐MSH-­‐3H10-­‐6-­‐4	   hybridoma	  
supernatant	  
mouse	   SHRVRPFRWHAPLKDC	  (PJ	  
127)	  
1-­‐MSH-­‐4B3-­‐1-­‐3	   hybridoma	  
supernatant	  
mouse	   SHRVRPFRWHAPLKDC	  (PJ	  
127)	  
1-­‐MSH-­‐4F12-­‐4-­‐6	   hybridoma	  
supernatant	  




2-­‐MSH-­‐3A1-­‐1-­‐1	   hybridoma	  
supernatant	  
mouse	   SYRMRHFRWHAPLKDC	  (PJ	  
128)	  
2-­‐MSH-­‐4E5-­‐2-­‐1	   hybridoma	  
supernatant	  
mouse	   SYRMRHFRWHAPLKDC	  (PJ	  
128)	  
2-­‐MSH-­‐4G11-­‐1-­‐1	   hybridoma	  
supernatant	  
mouse	   SYRMRHFRWHAPLKDC	  (PJ	  
128)	  
5-­‐MSH-­‐1G10-­‐1-­‐A7	   hybridoma	  
supernatant	  
mouse	   SYRMRHFRWHAPLKDC	  (PJ	  
128)	  
5-­‐MSH-­‐1G6-­‐1-­‐H1	   hybridoma	  
supernatant	  
mouse	   SYRMRHFRWHAPLKDC	  (PJ	  
128)	  
γ-­‐MSH	   Tyto	  alba	  
and	  Strix	  
aluco	  
3-­‐MSH-­‐1B10-­‐11-­‐1	  	  	   hybridoma	  
supernatant	  
mouse	   YVMSHFRWNKFGC	  (PJ	  125)	  
3-­‐MSH-­‐2H1-­‐1-­‐1	   hybridoma	  
supernatant	  
mouse	   YVMSHFRWNKFGC	  (PJ	  125)	  
3-­‐MSH-­‐3G4-­‐4-­‐3	   hybridoma	  
supernatant	  
mouse	   YVMSHFRWNKFGC	  (PJ	  125)	  
3-­‐MSH-­‐3B6-­‐4-­‐4	   hybridoma	  
supernatant	  
mouse	   YVMSHFRWNKFGC	  (PJ	  125)	  
3-­‐MSH-­‐4D1-­‐2-­‐2	   hybridoma	  
supernatant	  
mouse	   YVMSHFRWNKFGC	  (PJ	  125)	  
6-­‐MSH-­‐1M8-­‐8-­‐F12	   hybridoma	  
supernatant	  
mouse	   YVMSHFRWNKFGC	  (PJ	  125)	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6-­‐MSH-­‐1B12-­‐C1-­‐6	   hybridoma	  
supernatant	  
mouse	   YVMSHFRWNKFGC	  (PJ	  125)	  
6-­‐MSH-­‐1B12-­‐F8-­‐5	   hybridoma	  
supernatant	  
mouse	   YVMSHFRWNKFGC	  (PJ	  125)	  
	  
Table	  2.	  Library	  of	  custom	  antibodies	  raised	  against	  different	  species	  and	  different	  peptides	  included	  in	  the	  
POMC	  protein.	  
	  
B.	  WESSEL	  AND	  FLUEGGE	  PRECIPITATION	  PROTOCOL	  
400μl	  of	  supernatant	  were	  mixed	  in	  eppendorf	  tubes	  with	  400μl	  methanol	  and	  100μl	  chloroform.	  The	  
eppendorf	  tubes	  were	  vortexed	  for	  1min	  at	  12000rpm.	  Proteins	  were	  then	  located	  between	  two	  liquid	  
phases	  and	  the	  upper	  phase	  is	  removed.	  Further	  400μl	  of	  methanol	  were	  added,	  and	  the	  Eppendorf	  
tubes	  were	  inverted	  5	  times	  and	  centrifuged	  1min	  at	  13000rpm.	  The	  upper	  liquid	  phase	  was	  removed	  
and	  the	  pellet	  was	  left	  to	  dry	  for	  5min.	  Finally,	  to	  resuspend	  protein	  content,	  50μl	  of	  water	  and	  10μl	  of	  
6x	  SDS	  were	  added	  in	  the	  tubes	  and	  heated	  at	  95°C	  for	  8min.	  The	  Eppendorf	  tubes	  were	  vortexed	  to	  
better	  dissolve	  the	  proteins	  prior	  gel	  loading	  for	  WB	  analysis.	  
	  
C.	  STANDARD	  WESTERN	  BLOTTING	  AND	  COOMASSIE	  PROTOCOL	  
Samples	  were	  diluted	  in	  2x	  SDS-­‐PAGE	  (sodium	  dodecyl	  phosphate	  –	  polyacrylamide	  gel)	  containing	  10%	  
Dithiothreitol	  (DTT)	  and	  boiled	  5min	  at	  95°	  before	  loading.	  Proteins	  were	  separated	  in	  a	  SDS-­‐PAGE	  gel	  
composed	  of	  a	  stacking	  and	  a	  running	  part.	  In	  order	  to	  allow	  the	  proteins	  to	  reach	  the	  running	  gel,	  80V	  
current	  was	  applied.	  Current	  was	  then	  increased	  to	  120V	  for	  1h	  in	  order	  to	  allow	  the	  migration	  of	  the	  
polypeptides	  and	  the	  markers	  through	  the	  electrophoresis	  gel	  (12%	  gels).	  
In	  order	  to	  do	  a	  coomassie	  blue	  staining,	  gels	  were	  incubated	  with	  coomassie	  blue	  made	  of	  0.025%	  
Coomassie	  brilliant	  blue	  R250,	  40%	  methanol	  and	  7%	  acetic	  acid	  for	  1h,	  and	  washed	  overnight	  with	  
destaining	  solution	  made	  of	  67%	  dH2O,	  25%	  methanol	  and	  7.5%	  acetic	  acid	  in	  order	  to	  remove	  the	  dye	  
in	  excess	  from	  the	  gel.	  The	  coomassie	  blue	  staining	  solution	  was	  prepared	  by	  adding	  2.5g	  of	  coomassie	  
blue	  dye,	  455ml	  of	  ethanol,	  455ml	  of	  water,	  and	  90ml	  of	  glacial	  acetic	  acid.	  The	  destaining	  solution	  was	  
composed	  of	  455ml	  of	  ethanol,	  455ml	  water,	  and	  90ml	  of	  glacial	  acetic	  acid.	  
For	  Western	  blotting	  analysis,	  separated	  proteins	  on	  the	  gels	  were	  transferred	  to	  a	  nitrocellulose	  
membrane,	  and	  then	  blocked	  by	  3%	  milkpowder	  in	  PBST	  (Phosphate	  Buffer	  Solution	  with	  0.1%	  Tween-­‐
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20).	  Membranes	  were	  incubated	  overnight	  with	  the	  appropriate	  primary	  antibody,	  being	  either	  anti-­‐HA	  
antibody	  (Roche	  Diagnostics),	  anti-­‐V5	  antibody	  (Life	  Technologies)	  or	  one	  of	  the	  custom	  antibodies	  
present	  in	  our	  antibody	  library.	  The	  next	  day,	  membranes	  were	  washed	  twice	  with	  PBST	  (20min)	  and	  an	  
HRP-­‐linked	  secondary	  antibody	  was	  added	  for	  1h	  at	  room	  temperature.	  To	  reveal	  the	  proteins,	  
membranes	  were	  then	  washed	  with	  PBS	  1X	  0.2	  Tween-­‐20	  and	  revealed	  with	  the	  Advansta	  
Westernbright	  kit	  according	  to	  the	  manufacturer’s	  protocol.	  
	  
D.	  STANDARD	  ELISA	  PROTOCOL	  
For	  all	  ELISA	  done	  in	  this	  work,	  unless	  differently	  specified,	  this	  protocol	  has	  been	  applied:	  
Proteins	  of	  interest	  are	  diluted	  in	  1%	  Bovine	  Serum	  Albumin	  (BSA)	  in	  PBS	  	  and	  used	  to	  coat	  a	  96	  wells	  
plate	  overnight	  in	  the	  cold	  room	  at	  4°C.	  The	  next	  day,	  wells	  are	  washed	  three	  times	  with	  PBS.	  
200μL/well	  of	  1%	  BSA	  in	  PBS	  	  are	  added	  and	  incubated	  1h	  at	  room	  temperature	  in	  order	  to	  prevent	  
unspecific	  binding.	  Primary	  antibodies	  are	  diluted	  in	  1%	  BSA	  in	  PBS	  	  at	  appropriate	  concentrations	  and	  
added	  to	  the	  wells.	  After	  overnight	  incubation	  in	  the	  cold	  room,	  wells	  are	  washed	  three	  times	  with	  PBST	  
0.1%	  Tween-­‐20.	  The	  appropriate	  secondary	  antibodies	  are	  added	  and	  the	  plates	  are	  incubated	  1h	  at	  
room	  temperature.	  
	  
As	  secondary	  antibodies,	  anti-­‐rat	  and	  anti-­‐mouse	  antibodies	  (depending	  on	  the	  primary	  antibody	  used)	  
are	  diluted	  1:3000	  for	  1h	  at	  room	  temperature.	  The	  wells	  are	  washed	  three	  times	  with	  PBST.	  Finally,	  the	  
wells	  are	  washed	  three	  times	  with	  PBST,	  prior	  detection.	  	  
Detection	  is	  achieved	  as	  follows:	  Fresh	  OPD	  solution	  is	  made	  with	  10μL	  H2O2	  added	  to	  12,5ml	  of	  
phosphate	  citrate	  buffer	  and	  one	  tablet	  of	  OPD	  (Sigma-­‐Aldrich).	  The	  solution	  is	  vortexed	  thoroughly	  
until	  the	  reagent	  is	  dissolved.	  100μl	  of	  OPD	  solution	  are	  added	  in	  every	  well	  and	  incubated	  15min	  at	  
room	  temperature.	  The	  ELISA	  plate	  is	  then	  read	  at	  450nm.	  80μl	  of	  sulfuric	  acid	  2,5M	  is	  added	  in	  every	  
well	  to	  block	  the	  reaction.	  The	  ELISA	  plate	  is	  read	  again	  at	  490nm.	  
	  
E.	  IN	  VITRO	  ASSAYS	  
All	  conditioned	  media	  were	  provided	  by	  EPFL	  platform.	  In	  vitro	  digestions	  were	  performed	  using	  10μl	  of	  
conditioned	  PC-­‐1/3	  and	  PC-­‐2	  media,	  86μl	  of	  buffer	  of	  variable	  pHs	  (Phosphate	  or	  citrate	  final	  
concentration	  90mM),	  2μl	  of	  CaCl2	  (2mM	  final	  concentration)	  and	  2μl	  of	  Pyr-­‐RTRK-­‐MCA	  substrate	  (final	  
concentration	  5μM).	  Enzyme	  activity	  was	  read	  as	  fluorescence	  increase	  over	  time,	  monitoring	  the	  
release	  of	  the	  fluorescent	  AMC	  group	  (λex	  350nm;	  λem	  450nm)	  using	  a	  Berthold	  Tristar	  LB941	  reader.	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Data	  were	  elaborated	  using	  GraphPaD.	  	  
Regarding	  the	  competition	  assays,	  conditioned	  media	  containing	  either	  PC-­‐1/3	  or	  PC-­‐2	  were	  pre-­‐
incubated	  20min	  with	  increasing	  amount	  of	  conditioned	  media	  containing	  POMC	  protein	  at	  room	  
temperature.	  The	  solutions	  contained	  90mM	  of	  Acetate	  buffer	  	  and	  2mM	  of	  CaCl2	  	  (pH	  5	  for	  PC-­‐2	  and	  pH	  
5.5	  for	  PC-­‐1/3).	  Following	  the	  pre-­‐incubation,	  substrate	  was	  added	  and	  reading	  over	  time	  was	  achieved	  
as	  described	  above.	  	  
	  
F.	  PURIFICATION	  OF	  POMC	  FROM	  THE	  THE	  SUPERNATANT	  BY	  AFFINITY	  	  CHROMATOGRAPHY	  OR	  
IMMUNOPRECIPITATION	  
Purification	  by	  affinity	  (anti-­‐HA	  and	  anti-­‐V5)	  chromatography	  was	  done	  using	  anti-­‐HA	  and	  anti-­‐V5	  
matrices	  and	  a	  peristaltic	  pump.	  The	  matrices	  were	  equilibrated	  using	  10	  bed	  volumes	  (20ml)	  of	  
equilibration	  buffer	  made	  of	  20	  mM	  Tris,	  pH	  7.5,	  0.1	  M	  NaCl,	  0.1	  mM	  EDTA.	  The	  flow	  rate	  was	  adjusted	  
to	  1	  ml/min.	  
The	  affinity	  column	  was	  loaded	  with	  8	  ml	  of	  SA-­‐POMC	  supernatant,	  the	  flow	  rate	  adjusted	  to	  0.8	  
ml/min,	  and	  the	  column	  sealed	  with	  parafilm.	  
The	  column	  was	  washed	  with	  20	  bed	  volumes	  (40ml)	  washing	  buffer	  made	  of	  20	  mM	  Tris,	  pH	  7.5,	  0.1	  M	  
NaCl,	  0.1	  mM	  EDTA	  and	  0.05%	  Tween	  20.	  For	  the	  anti-­‐V5	  column,	  PBS	  was	  used	  as	  wash	  buffer.	  	  
For	  elution,	  1	  bed	  volume	  (2ml)	  of	  HA	  or	  V5	  peptides	  reconstituted	  to	  1	  mg/ml	  in	  equilibration	  buffer	  
were	  added	  to	  the	  column	  and	  incubated	  15	  min	  at	  37°C.	  Elution	  fractions	  were	  then	  collected	  in	  an	  
eppendorf	  tube.	  Elution	  was	  repeated	  three	  more	  times	  in	  order	  to	  obtain	  4	  elution	  fractions.	  Samples	  
were	  kept	  at	  2-­‐8°C	  until	  final	  analysis.	  In	  order	  to	  regenerate	  the	  column	  for	  further	  use,	  HA	  peptide	  was	  
removed	  from	  the	  column	  with,	  20	  bed	  volumes	  (40ml)	  of	  regeneration	  buffer	  (0.1	  mM	  glycine,	  pH	  2),	  
followed	  by	  re-­‐equilibration	  of	  the	  column	  with	  20	  bed	  volumes	  (40ml)	  of	  equilibration	  buffer.	  
	  
Supernatant	  purification	  was	  also	  performed	  using	  magnetic	  Dynabeads	  coupled	  to	  custom	  antibody	  1-­‐
ACTH-­‐1E3-­‐4-­‐1.	  Dynabeads	  were	  resuspended	  and	  20μl	  each	  transferred	  to	  three	  eppendorf	  tubes.	  The	  
tubes	  were	  placed	  on	  a	  magnet	  and	  supernatant	  was	  removed	  and	  discarded.	  In	  order	  to	  coat	  the	  beads	  
with	  the	  antibodies,	  10μl	  of	  PBST	  (negative	  control),	  anti-­‐HA	  antibody	  (negative	  control)	  and	  custom	  
antibody	  1-­‐ACTH-­‐1E3-­‐4-­‐1	  were	  added	  each	  into	  the	  bead	  containing	  Eppendorf	  tubes,	  along	  with	  200μl	  
PBST.	  The	  tubes	  were	  incubated	  in	  a	  rotating	  wheel	  for	  30	  min	  at	  room	  temperature,	  put	  on	  a	  magnet	  
and	  the	  supernatant	  was	  removed	  and	  discarded.	  The	  bead-­‐antibody	  complexes	  were	  resuspended	  in	  
200μl	  PBST.	  The	  tubes	  were	  placed	  on	  a	  magnet	  and	  the	  supernatant	  was	  removed.	  250μl	  SA-­‐POMC	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sample	  was	  then	  added	  and	  incubated	  at	  4°C	  overnight	  in	  a	  rotating	  wheel.	  The	  tubes	  were	  washed	  
three	  times	  with	  1ml	  PBS	  1X.	  50μl	  1%	  SDS	  buffer	  were	  added	  to	  each	  tube	  and	  incubated	  10	  min	  at	  70°C	  
in	  order	  to	  elute	  the	  desired	  protein.	  
	  
V.	  RESULTS	  
A.	  ANALYSIS	  OF	  EPFL	  LARGE-­‐SCALE	  PRODUCTION	  
Plasmids	  of	  Hu-­‐POMC,	  SA-­‐POMC,	  and	  TA-­‐POMC	  were	  tagged	  with	  HA	  and	  V5	  epitope	  whereas	  PC-­‐1/3	  
and	  PC-­‐2	  were	  only	  tagged	  with	  V5	  epitope.	  Plasmids	  encoding	  each	  protein	  were	  amplified	  to	  final	  
1.5mg	  (according	  to	  manufacturer’s	  protocol)	  which	  is	  the	  quantity	  required	  for	  0.5L	  production	  of	  
conditioned	  media	  by	  cell	  suspension.	  Proteins	  were	  produced	  in	  HEK293	  cells	  by	  the	  EPFL	  platform	  
directed	  by	  Dr.	  Hacker.	  In	  order	  to	  assess	  the	  quality	  of	  the	  production,	  Hu-­‐POMC,	  SA-­‐POMC,	  TA-­‐POMC,	  
PC-­‐1/3,	  and	  PC-­‐2	  samples	  were	  separated	  on	  a	  12%	  SDS-­‐PAGE	  gel	  after	  a	  Wessel	  &	  Flügge	  precipitation.	  
The	  Coomassie	  gel	  showed	  an	  overall	  good	  amount	  of	  the	  different	  proteins	  contained	  in	  the	  
supernatant	  provided	  by	  the	  EPFL	  platform,	  with	  the	  exception	  of	  PC-­‐2.	  Hu-­‐POMC	  was	  present	  at	  high	  
concentrations	  (Fig.3).	  Two	  western	  blots	  were	  then	  made.	  The	  first	  was	  loaded	  with	  Hu-­‐POMC,	  SA-­‐
POMC,	  TA-­‐POMC,	  PC-­‐1/3	  and	  PC-­‐2	  and	  revealed	  with	  anti-­‐V5	  antibody	  (Fig.	  4A	  –low	  exposure-­‐	  and	  B	  –	  
high	  exposure).	  The	  second	  was	  loaded	  with	  Hu-­‐POMC,	  SA-­‐POMC,	  TA-­‐POMC	  and	  revealed	  with	  anti-­‐HA	  
antibody	  (Fig.	  3C).	  Molecular	  weights	  of	  all	  proteins	  fit	  the	  expectations.	  Western	  blot	  analyses	  are	  in	  
line	  with	  the	  Coomassie	  results.	  Degradation	  products	  can	  be	  seen	  in	  the	  Hu-­‐POMC	  lanes	  of	  the	  HA-­‐
revealed	  western	  blots.	  
	  
Figure	  2.	  Coomassie	  gel	  of	  the	  different	  POMC	  and	  PCs	  acquired	  through	  the	  EPFL	  platform.	  The	  gel	  was	  loaded	  
with	  Human,	  Strix	  aluco	  and	  Tyto	  alba	  POMCs,	  as	  well	  as	  with	  PC-­‐1/3	  and	  PC-­‐2,	  and	  revealed	  with	  Coomassie	  blue,	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showing	  good	  amount	  of	  the	  different	  proteins,	  particularly	  Hu-­‐POMC	  and	  PC-­‐1/3.	  The	  amount	  of	  proteins	  loaded	  
corresponds	  to	  400μl	  of	  original	  cell	  supernatant	  before	  Wessel	  and	  Fluegge.	  
	  
Figure	  3.	  Western	  blots	  of	  the	  different	  POMCs	  and	  PCs	  acquired	  through	  the	  EPFL	  platform.	  A.	  and	  B.	  The	  gels	  
were	  loaded	  with	  Human,	  Strix	  aluco	  and	  Tyto	  alba	  POMCs,	  as	  well	  as	  with	  PC-­‐1/3	  and	  PC-­‐2,	  and	  revealed	  with	  
anti-­‐V5	  antibody.	  Hu-­‐POMC	  shows	  a	  certain	  amount	  of	  degradation	  products	  still	  containing	  the	  V5	  tag.	  C.	  The	  gel	  
was	  loaded	  with	  Human,	  Strix	  aluco	  and	  Tyto	  alba	  POMC	  and	  revealed	  with	  anti-­‐HA.	  
	  
The	  87kDa,	  81kDa	  and	  63kDa	  forms	  of	  PC-­‐1/3	  are	  visible	  [12].	  The	  unprocessed	  protein	  seems	  to	  be	  
present	  in	  larger	  amounts	  than	  the	  mature	  forms,	  in	  line	  with	  the	  expectations	  (Fig.	  3A	  and	  3B).	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The	  overall	  production	  was	  quantitatively	  
acknowledged	  as	  adequate	  for	  the	  purpose	  of	  the	  
further	  experiments.	  	  
	  
Next,	  we	  wanted	  to	  verify	  whether	  PC-­‐1/3	  and	  
PC-­‐2	  retained	  their	  enzymatic	  activities.	  To	  this	  
purpose,	  we	  analyzed	  in	  vitro	  the	  ability	  of	  the	  
conditioned	  media	  (PC-­‐1/3	  and	  PC-­‐2)	  to	  cleave	  
the	  fluorogenic	  substrate	  Ac-­‐RTKR-­‐MCA,	  carrying	  
the	  basic	  PC	  consensus	  sequence	  Basic-­‐Xn-­‐Basic.	  
Conditioned	  media	  containing	  SA-­‐POMC	  was	  
taken	  as	  negative	  control.	  Briefly,	  85µL	  of	  
supernatant	  was	  incubated	  with	  5µM	  substrate	  in	  
buffer	  solutions	  covering	  the	  pH	  range	  4.0-­‐7.5	  
(see	  materials	  and	  methods	  for	  details).	  Reading	  
of	  the	  released	  AMC	  fluorescence	  over	  time	  
revealed	  that	  our	  preparations	  contained	  active	  
enzymes	  within	  the	  expected	  pH	  values.	  In	  
contrast	  the	  POMC	  conditioned	  medium	  showed	  
no	  	  enzymatic	  activities	  (Fig.	  4).	  
	  
Finally,	  we	  investigated	  the	  ability	  of	  POMC	  to	  compete	  with	  the	  synthetic	  Ac-­‐RTKR-­‐MCA	  substrate.	  The	  
competition	  gives	  an	  idea	  of	  the	  affinity	  of	  the	  natural	  vs	  synthetic	  substrate.	  	  
Briefly,	  PC-­‐1/3	  and	  PC-­‐2	  media	  were	  pre-­‐incubated	  with	  increasing	  volumes	  of	  Hu-­‐,	  TA-­‐	  SA-­‐POMC	  
conditioned	  media	  in	  acidic	  conditions.	  20min	  post-­‐incubation	  5µM	  Ac-­‐RTKR-­‐MCA	  was	  added	  and	  
fluorescence	  monitored	  as	  reported	  above.	  The	  presence	  of	  POMC	  did	  not	  have	  any	  effect	  on	  PC-­‐2.	  In	  
contrast,	  we	  observed	  a	  trend	  for	  up-­‐regulation	  of	  PC-­‐1/3	  enzymatic	  activity	  proportionally	  to	  the	  
amount	  of	  POMC	  present	  in	  solution	  (Fig.	  5.).	  
Overall,	  the	  in	  vitro	  analysis	  of	  PC-­‐1/3	  and	  PC-­‐2	  demonstrated	  good	  enzymatic	  activities	  against	  a	  
synthetic	  fluorogenic	  substrate.	  PC-­‐1/3	  activity	  seems	  to	  be	  increased	  in	  the	  presence	  of	  high	  POMC	  
concentrations.	  
	  
Figure	  4.	  	  Released	  fluorescence	  over	  time	  at	  
different	  pH	  for	  PC-­‐1/3	  and	  PC-­‐2	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Figure	  5.	  Competitive	  assay	  of	  PC-­‐1/3	  and	  PC-­‐2	  protein	  convertases	  against	  Pyr-­‐RTRK-­‐MCA	  substrate	  and	  TA-­‐,	  
SA-­‐,	  and	  Hu-­‐POMC.	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B.	  PURIFICATION	  OF	  POMC	  
POMCs	  and	  enzymes	  were	  needed	  for	  in	  vitro	  studies,	  which	  required	  high	  levels	  of	  purity.	  In	  order	  to	  
purify	  the	  proteins,	  two	  affinity	  purifications	  of	  SA-­‐POMC	  were	  carried	  out	  using	  either	  anti-­‐HA	  or	  anti-­‐
V5	  agarose	  bead	  affinity	  columns	  (Fig.	  6.).	  
	  
Figure	  6.	  Affinity	  purification	  using	  agarose	  matrix	  cross-­‐linked	  to	  IgG	  antibodies.	  A.	  The	  mixture	  containing	  the	  
protein	  of	  interest	  is	  added	  to	  the	  column.	  B.	  The	  undesired	  components	  are	  washed	  away	  with	  washing	  buffer.	  C.	  
The	  protein	  of	  interest	  is	  eluted	  into	  a	  separate	  aliquot.	  
	  
Firstly,	  0.5L	  of	  supernatant	  were	  loaded	  overnight	  on	  an	  anti-­‐HA	  matrix	  using	  a	  peristaltic	  pump	  
(0.5mL/min).	  The	  flow-­‐through	  and	  a	  sample	  of	  input	  were	  kept	  in	  order	  to	  perform	  a	  coomassie	  gel	  to	  
control	  the	  efficiency	  of	  the	  purification.	  POMC	  was	  eluted	  using	  anti-­‐HA	  or	  anti-­‐V5	  peptide	  adjusted	  to	  
1mg/ml	  in	  equilibration	  buffer	  as	  described	  in	  materials	  and	  methods.	  The	  analysis	  revealed	  that	  the	  SA-­‐
POMC	  was	  not	  purified	  since	  it	  was	  fully	  recovered	  in	  the	  flow-­‐through	  (Fig.7	  A).	  In	  a	  second	  attempt,	  
the	  same	  protein	  was	  loaded	  onto	  an	  anti-­‐V5	  column,	  following	  a	  protocol	  similar	  to	  that	  described	  
above.	  Also	  in	  this	  case,	  the	  coomassie	  gel	  showed	  huge	  amount	  of	  proteins	  in	  the	  flowthrough	  (Fig.7	  B).	  
No	  traces	  of	  SA-­‐POMC	  were	  detected	  in	  the	  eluates,	  suggesting	  that	  none	  of	  the	  tagged	  POMC	  bound	  to	  
neither	  HA-­‐	  nor	  V5-­‐antibodies.	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Figure	  7.	  Coomassie	  gels	  of	  SA-­‐POMC	  after	  HA-­‐	  and	  V5-­‐	  affinity	  purification.	  Following	  HA	  (A.)	  or	  V5	  (B.)	  affinity	  
purifications,	  flowthrough	  and	  input	  were	  loaded	  with	  and	  without	  WF	  procedure.	  4	  sequential	  elutions	  were	  
performed	  and	  samples	  loaded.	  (Ft:	  flowthrough;	  WF:	  Wessel	  &	  Fluegge)	  
	  
C.	  CHARACTERIZATION	  OF	  ANTIBODIES	  AGAINST	  POMC:	  	  	  
Our	  lab	  has	  a	  library	  of	  antibodies	  raised	  against	  POMC	  (see	  materials	  &	  methods	  for	  details)	  to	  be	  fully	  
characterized.	  We	  initially	  wanted	  to	  use	  purified	  protein	  for	  this	  analysis	  but	  the	  inability	  to	  purify	  
POMC	  forced	  us	  to	  use	  raw	  material	  (supernatants	  from	  HEK	  cells	  overexpressing	  POMC).	  The	  
antibodies	  were	  tested	  using	  two	  approaches:	  1.	  ELISA,	  which	  is	  based	  on	  native	  protein	  conformation;	  
2.	  Western	  blotting,	  which	  requires	  protein	  denaturation.	  
	  
PART	  1:	  ELISA	  	  
ELISA	  test	  was	  performed	  against	  all	  POMCs.	  Briefly,	  96-­‐well	  plates	  were	  coated	  with	  POMC	  containing	  
medium,	  as	  well	  as	  PC-­‐2	  containing	  medium	  and	  BSA	  (negative	  controls).	  As	  a	  positive	  control,	  C-­‐
terminally	  V5	  tagged	  POMC	  was	  revealed	  with	  anti-­‐V5	  antibodies	  to	  verify	  proper	  coating.	  Primary	  
antibodies	  were	  used	  undiluted.	  ELISA	  readout	  followed	  the	  procedure	  described	  in	  materials	  and	  
methods.	  
	   	  Tyto	  alba	  β-­‐MSH	  antibodies:	  None	  of	  the	  anti	  Tyto	  alba	  β-­‐MSH	  antibodies	  did	  recognize	  specifically	  
POMC.	  Antibodies	  1-­‐MSH-­‐2B1-­‐1-­‐1	  and	  1-­‐MSH-­‐3F2-­‐1-­‐4	  that	  displayed	  some	  activity	  towards	  β	  -­‐MSH	  also	  
yielded	  a	  positive	  signal	  in	  wells	  coated	  with	  medium	  from	  PC2,	  but	  not	  POMC	  expressing	  cells.	  These	  
antibodies	  therefore	  unspecifically	  detect	  another	  component	  in	  the	  supernatant.	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   Strix	  aluco	  β-­‐MSH	  antibodies:	  In	  contrast,	  anti	  Strix	  aluco	  antibodies	  2-­‐MSH-­‐3A1-­‐1-­‐1	  and	  5-­‐MSH-­‐
1G6-­‐1-­‐H1	  gave	  signals	  superior	  to	  the	  PC-­‐2	  negative	  control.	  5-­‐MSH-­‐1G6-­‐1-­‐H1	  antibody	  bound	  both,	  
human	  and	  Strix	  aluco	  POMC,	  but	  not	  Tyto	  alba	  POMC.	  2-­‐MSH-­‐3A1-­‐1-­‐1	  did	  not	  recognize	  the	  β-­‐MSH	  
epitope	  within	  Strix	  aluco	  POMC,	  the	  species,	  the	  b-­‐MSH	  peptide	  for	  immunization	  was	  derived	  from,	  
but	  recognized	  human	  POMC.	  We	  acknowledge	  that	  the	  medium	  from	  human	  POMC	  overexpressing	  
HEK	  cells	  contained	  higher	  POMC	  content	  than	  the	  medium	  from	  Strix	  aluco	  expressing	  HEK	  cells.	  	  
	  
	   ACTH	  antibodies:	  Most	  of	  the	  antibodies	  raised	  against	  ACTH	  worked	  well	  against	  their	  epitopes	  in	  
POMC,	  usually	  without	  significant	  specificity	  for	  the	  species	  they	  were	  raised	  against	  (cross	  species	  
activity).	  	  
	   	  
	   Strix	  aluco/Tyto	  alba	  γ-­‐MSH	  antibodies:	  antibodies	  3-­‐MSH-­‐3B6-­‐4-­‐4	  and	  6-­‐MSH-­‐1B12-­‐F8-­‐5	  reacted	  
with	  POMC	  of	  all	  species,	  the	  latter	  being	  much	  more	  specific	  with	  low	  PC-­‐2	  medium	  cross	  reactivity.	  
	  
	  	  	  	  	   	  
Figure	  8.	  Summary	  of	  ELISA	  of	  the	  custom	  antibodies	  against	  TA-­‐,	  SA-­‐,	  and	  Hu-­‐POMC.	  Positive	  control	  was	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Overall,	  POMC	  recognition	  by	  the	  anti-­‐ACTH	  antibodies	  was	  better	  than	  with	  the	  other	  tested	  
antibodies,	  with	  antibodies	  A-­‐1A12,	  1-­‐ACTH-­‐1E3-­‐4-­‐1,	  1-­‐ACTH-­‐2G9-­‐4-­‐1	  showing	  reactivity	  superior	  even	  
to	  the	  positive	  control.	  Interestingly,	  the	  anti-­‐MSHs	  antibodies	  specifically	  raised	  against	  owl	  sequences,	  	  
antibodies	  A-­‐1A12	  and	  A-­‐2A3	  raised	  against	  human	  ACTH	  as	  well	  as	  1-­‐ACTH-­‐1E3-­‐4-­‐1	  and	  1-­‐ACTH-­‐2G9-­‐4-­‐
1	  raised	  against	  owl	  ACTH,	  	  all	  recognized	  their	  respective	  epitopes	  in	  human	  as	  well	  as	  owl	  POMC.	  	  
	  
PART	  2:	  WESTERN	  BLOTTING	  	  
The	  antibodies	  that	  showed	  a	  significant	  ELISA	  response	  were	  further	  tested	  in	  western	  blot	  analysis.	  	  
Briefly,	  20µL	  of	  EPFL	  conditioned	  medium	  containing	  Hu-­‐,	  SA-­‐,	  TA-­‐	  POMC	  were	  loaded	  on	  a	  12%	  SDS-­‐
PAGE	  gel.	  PC-­‐1/3	  medium	  was	  taken	  as	  negative	  control	  to	  eventually	  identify	  antibody	  cross-­‐reactivity	  
with	  unspecific	  proteins	  present	  in	  the	  medium.	  Each	  membrane	  was	  split	  into	  three	  to	  be	  revealed	  with	  
two	  custom	  antibodies	  as	  primary	  antibodies	  and	  with	  anti-­‐HA	  as	  primary	  antibody	  for	  positive	  control	  
to	  confirm	  the	  presence	  of	  POMC.	  The	  results	  of	  the	  Western	  blots	  were	  in	  line	  with	  those	  obtained	  with	  
the	  ELISA.	  A	  discrepancy	  was	  found	  for	  the	  antibody	  SC-­‐57018	  which	  specifically	  recognized	  Hu-­‐POMC	  in	  
WB	  but	  not	  ELISA	  (Fig.	  9	  A.)	  and	  antibody	  2-­‐MSH-­‐3A1-­‐1-­‐1,	  which	  recognized	  not	  only	  human	  but	  also	  
Tyto	  alba	  POMC	  (Fig.	  12	  B).	  We	  also	  tested	  further	  three	  antibodies	  that	  were	  negative	  in	  ELISA:	  the	  
antibody	  1-­‐MSH-­‐3F2-­‐1-­‐4	  showed	  cross-­‐reactivity	  in	  ELISA	  with	  the	  PC-­‐2	  medium.	  In	  WB,	  we	  found	  that	  
1-­‐MSH-­‐3F2-­‐1-­‐4	  does	  correctly	  recognize	  the	  POMC	  precursor,	  but	  also	  a	  low	  molecular	  weight	  protein	  
that	  runs	  with	  the	  front,	  explaining	  therefore	  the	  unspecific	  stain	  of	  the	  ELISA	  negative	  control.	  In	  
contrast	  the	  antibody	  1-­‐MSH-­‐2B1-­‐1-­‐1,	  which	  also	  had	  some	  ELISA	  cross-­‐reactivity	  was	  able	  to	  bind	  to	  
Hu-­‐POMC	  specifically	  in	  WB.	  Finally,	  the	  antibody	  2-­‐MSH-­‐4G11-­‐1-­‐1	  was	  incapable	  to	  identify	  POMC	  in	  
WB	  in	  line	  with	  the	  ELISA	  results.	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Figure	  9.	  A.	  The	  membrane	  was	  revealed	  with	  antibody	  SC-­‐57018	  raised	  against	  human	  ACTH.	  B.	  The	  membrane	  
was	  revealed	  with	  antibody	  A-­‐1A12	  raised	  against	  human	  ACTH.	  C.	  Positive	  control,	  the	  membrane	  was	  revealed	  
with	  anti-­‐HA	  antibody.	  
	  
The	  membrane	  revealed	  with	  antibody	  SC-­‐57018	  recognized	  only	  Hu-­‐POMC	  as	  well	  as	  its	  degradation	  
products.	  This	  is	  consistent	  with	  the	  fact	  that	  this	  custom	  antibody	  was	  raised	  against	  human	  ACTH.	  
Despite	  the	  fact	  that	  antibody	  A-­‐1A12	  was	  raised	  against	  human	  ACTH,	  the	  membrane	  revealed	  with	  
this	  antibody	  was	  not	  specific	  to	  any	  of	  the	  species	  used	  and	  recognized	  all	  Hu-­‐,	  SA-­‐,	  and	  TA-­‐POMC,	  PC-­‐
1/3	  was	  also	  recognized	  but	  this	  is	  most	  likely	  due	  do	  spillage	  of	  the	  supernatant	  loaded	  in	  the	  Hu-­‐POMC	  
lane.	  	  	  
	  
Figure	  10.	  A.	  The	  membrane	  was	  revealed	  with	  antibody	  A-­‐2A3	  raised	  against	  human	  ACTH.	  B.	  The	  membrane	  was	  
revealed	  with	  antibody	  1-­‐ACTH-­‐1E3-­‐4-­‐1	  raised	  against	  owl	  ACTH.	  C.	  Positive	  control,	  the	  membrane	  was	  revealed	  
with	  anti-­‐HA	  antibody.	  
	  
The	  membrane	  revealed	  with	  antibody	  A-­‐2A3	  also	  recognized	  all	  POMC	  but	  Hu-­‐POMC	  more	  specifically	  
than	  SA-­‐	  and	  TA-­‐POMC,	  which	  is	  consistent	  with	  the	  fact	  that	  it	  was	  also	  raised	  against	  human	  ACTH.	  	  
Antibody	  1-­‐ACTH-­‐1E3-­‐4-­‐1	  was	  raised	  against	  owl	  ACTH	  and	  recognized	  all	  POMCs	  as	  well,	  with	  higher	  
affinity	  for	  the	  owl	  POMCs	  and	  recognized	  degradation	  products	  better	  in	  the	  owl	  samples	  than	  the	  
human	  one.	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Figure	  11.	  A.	  The	  membrane	  was	  revealed	  with	  antibody	  1-­‐ACTH-­‐2G9-­‐4-­‐1	  raised	  against	  owl	  ACTH.	  B.	  The	  
membrane	  was	  revealed	  with	  antibody	  1-­‐MSH-­‐2B1-­‐1-­‐1	  raised	  against	  Tyto	  alba	  β-­‐MSH.	  C.	  Positive	  control,	  the	  
membrane	  was	  revealed	  with	  anti-­‐HA	  antibody.	  
	  
Antibody	  1-­‐ACTH-­‐2G9-­‐4-­‐1	  was	  raised	  against	  owl	  ACTH	  and	  recognized	  each	  POMC	  as	  well	  as	  their	  
degradation	  products.	  	  Antibody	  1-­‐MSH-­‐2B1-­‐1-­‐1	  was	  raised	  against	  owl	  β-­‐MSH	  and	  recognized	  almost	  
Hu-­‐POMC.	  We	  can	  see	  a	  light	  band	  in	  the	  TA-­‐POMC	  line	  as	  well.	  The	  better	  recognition	  of	  human	  POMC	  
is	  likely	  due	  to	  the	  higher	  POMC	  amount	  in	  this	  lane	  compared	  to	  the	  Tyto	  alba	  POMC	  lane.	  We	  cannot	  
see	  degradation	  products	  of	  POMC	  indicating	  that	  the	  degradation	  products	  might	  not	  contain	  the	  β-­‐
MSH	  part	  of	  the	  protein.	  
	  
Figure	  12.	  A.	  The	  membrane	  was	  revealed	  with	  antibody	  1-­‐MSH-­‐3F2-­‐1-­‐4	  raised	  against	  Tyto	  alba	  β-­‐MSH.	  B.	  The	  
membrane	  was	  revealed	  with	  antibody	  2-­‐MSH-­‐3A1-­‐1-­‐1	  raised	  against	  Strix	  aluco	  β-­‐MSH.	  C.	  Positive	  control,	  the	  
membrane	  was	  revealed	  with	  anti-­‐HA	  antibody.	  
	  
Antibody	  1-­‐MSH-­‐3F2-­‐1-­‐4	  was	  raised	  against	  Tyto	  alba	  β-­‐MSH	  and	  recognized	  each	  POMC	  but	  with	  low	  
sensitivity	  since	  the	  exposure	  had	  to	  be	  raised	  high	  in	  order	  to	  see	  the	  bands	  clearly.	  Antibody	  2-­‐MSH-­‐
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3A1-­‐1-­‐1	  was	  raised	  against	  Strix	  aluco	  β-­‐MSH	  and	  recognized	  Hu-­‐POMC	  and	  TA-­‐POMC	  better	  than	  SA-­‐
POMC.	  	  
	  
Figure	  13.	  A.	  The	  membrane	  was	  revealed	  with	  antibody	  5-­‐MSH-­‐1G6-­‐1-­‐H1	  raised	  against	  Strix	  aluco	  β-­‐MSH.	  B.	  The	  
membrane	  was	  revealed	  with	  antibody	  3-­‐MSH-­‐3B6-­‐4-­‐4	  raised	  against	  owl	  γ-­‐MSH.	  C.	  Positive	  control,	  the	  
membrane	  was	  revealed	  with	  anti-­‐HA	  antibody.	  
	  
Antibody	  5-­‐MSH-­‐1G6-­‐1-­‐H1	  was	  raised	  against	  Strix	  aluco	  β-­‐MSH	  and	  recognized	  SA-­‐POMC	  and	  Hu-­‐POMC	  
specifically.	  Antibody	  3-­‐MSH-­‐3B6-­‐4-­‐4	  was	  raised	  against	  owl	  γ-­‐MSH	  and	  recognized	  both	  human	  and	  owl	  
POMCs	  with	  higher	  specificity	  for	  human	  and	  overall	  low	  affinity	  since	  revealing	  the	  membrane	  required	  
high	  exposure.	  	  
	  
Figure	  14.	  A.	  The	  membrane	  was	  revealed	  with	  antibody	  6-­‐MSH-­‐1B12-­‐F8-­‐5	  raised	  against	  owl	  γ-­‐MSH.	  B.	  The	  
membrane	  was	  revealed	  with	  antibody	  2-­‐MSH-­‐4G11-­‐1-­‐1	  raised	  against	  Strix	  aluco	  β-­‐MSH.	  C.	  Positive	  control,	  the	  
membrane	  was	  revealed	  with	  anti-­‐HA	  antibody.	  
	  
Antibody	  6-­‐MSH-­‐1B12-­‐F8-­‐5	  was	  raised	  against	  owl	  γ-­‐MSH	  and	  recognized	  both	  human	  and	  owl	  POMCs.	  	  
Antibody	  2-­‐MSH-­‐4G11-­‐1-­‐1	  raised	  against	  Strix	  aluco	  β-­‐MSH	  which	  was	  taken	  randomly	  did	  not	  recognize	  
any	  of	  the	  POMCs.	  Overall,	  we	  successfully	  characterized	  the	  panel	  of	  POMC	  antibodies	  in	  our	  hands.	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Our	  analyses	  identified	  through	  both	  ELISA	  and	  western	  blotting	  several	  antibodies	  that	  can	  react	  with	  
POMC	  of	  different	  species	  in	  over-­‐expressed	  system.	  In	  table	  3,	  we	  summarize	  our	  results.	  Whether	  the	  
antibodies	  are	  sensitive	  enough	  to	  detect	  	  endogenous	  POMC	  in	  the	  according	  cell	  lines	  and	  tissues	  	  
remains	  to	  be	  tested.	  
	  




-­‐	   -­‐	   +	   -­‐	  
A-­‐1A12	  (Anne	  
White)	  
+	   +	   +	   -­‐	  
A-­‐2A3	  (Anne	  
White)	  
-­‐	   -­‐	   +	   +/-­‐	  
1-­‐ACTH-­‐1E3-­‐4-­‐1	   +++	   +++	   +++	   -­‐	  
1-­‐ACTH-­‐2G9-­‐4-­‐1	   +++	   +++	   +++	   -­‐	  
1-­‐MSH-­‐2B1-­‐1-­‐1	   -­‐	   -­‐	   +	   +/-­‐	  
1-­‐MSH-­‐3F2-­‐1-­‐4	   +	   +	   +	   +	  
2-­‐MSH-­‐3A1-­‐1-­‐1	   -­‐	   -­‐	   +	   -­‐	  
5-­‐MSH-­‐1G6-­‐1-­‐H1	   +++	   -­‐	   ++	   -­‐	  
3-­‐MSH-­‐3B6-­‐4-­‐4	   +++	   +++	   +++	   -­‐	  
6-­‐MSH-­‐1B12-­‐F8-­‐5	   +++	   +++	   +++	   -­‐	  
2-­‐MSH-­‐4G11-­‐1-­‐1	   -­‐	   -­‐	   -­‐	   -­‐	  
	  
Table	  3.	  Western	  blot	  summary	  of	  the	  antibodies’	  affinity	  against	  the	  different	  POMCs	  
	  
The	  table	  summarizes	  both	  ELISA	  and	  WB	  analyses.	  ELISA	  –WB	  discrepancies:	  For	  1-­‐MSH-­‐3F2-­‐1-­‐4	  
antibody,	  the	  bands	  are	  at	  the	  expected	  molecular	  weight,	  so	  it	  most	  probably	  detects	  the	  correct	  
protein	  even	  though	  in	  ELISA	  the	  PC-­‐2	  medium	  background	  was	  stronger	  than	  the	  POMC	  signal.	  It	  is	  
possible	  that	  PC-­‐1/3	  does	  not	  contain	  specific	  impurities	  present	  in	  PC-­‐2	  media	  or	  the	  cross	  reacting	  
components	  of	  the	  medium	  are	  denatured	  in	  Western	  blot	  and	  are	  no	  longer	  recognized	  by	  the	  
antibody.	  The	  other	  discrepancy	  found	  was	  the	  detection	  of	  Hu-­‐POMC	  by	  the	  SC-­‐57018	  antibody	  using	  
western	  blotting	  procedure	  as	  opposed	  to	  ELISA,	  which	  gives	  a	  signal	  below	  the	  negative	  control.	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D.	  USE	  OF	  POMC	  ANTIBODIES	  TO	  INVESTIGATE	  POMC	  MATURATION	  
In	  our	  lab,	  we	  are	  interested	  in	  POMC	  maturation	  and	  how	  this	  could	  be	  affected	  by	  the	  unusual	  
insertion	  of	  Poly-­‐Ser	  found	  in	  Tyto	  alba.	  In	  a	  first	  attempt,	  we	  tried	  to	  follow	  the	  multiple	  cleavages	  
using	  N-­‐	  and	  C-­‐	  terminal	  tags	  to	  POMC.	  However,	  this	  approach	  is	  limited	  since	  internal	  fragments,	  
which	  correspond	  to	  MSHs,	  are	  lost.	  To	  overcome	  this	  problem,	  we	  decided	  to	  use	  our	  newly	  
characterized	  antibodies.	  Briefly,	  an	  in	  vitro	  digestion	  was	  performed	  using	  supernatants	  from	  human	  
POMC	  overexpressing	  HEK	  cells	  and	  incubating	  them	  with	  either	  supernatants	  from	  PC-­‐2	  overexpressing	  
HEK	  cells	  or	  water.	  Samples	  were	  collected	  after	  incubation	  for	  different	  times	  (t=0	  ,	  t=6h,	  t=4	  days)	  and	  
immediately	  frozen	  at	  -­‐20C.	  Western	  blot	  analysis	  was	  carried	  out	  using	  antibodies	  directed	  against	  HA	  
and	  β-­‐MSH	  using	  the	  custom	  antibody	  5-­‐MSH-­‐1G6-­‐1-­‐H1.	  Results	  show	  that	  we	  do	  not	  detect	  any	  PC-­‐2	  
specific	  cleavage	  of	  POMC	  going	  beyond	  unspecific	  degradation,	  potentially	  due	  to	  the	  non-­‐optimal	  pH	  
in	  the	  supernatant	  (see	  your	  pH	  profile	  for	  PC-­‐2	  with	  the	  AMC-­‐peptide,	  optimal	  at	  around	  pH	  4.5,	  non	  
detectable	  at	  pH	  7).	  Also,	  we	  would	  need	  PC-­‐1/3	  to	  cleave	  POMC	  first	  in	  order	  to	  provide	  the	  substrate	  
for	  PC-­‐2,	  we	  would	  need	  to	  co-­‐overexpress	  POMC	  with	  PC-­‐1/3	  and	  PC-­‐2	  in	  HEK	  cells,	  so	  that	  the	  
cleavage	  can	  happen	  in	  the	  cell	  in	  the	  acidic	  secretory	  granules.	  Once	  released	  to	  the	  supernatant,	  the	  
pH	  is	  too	  high,	  ex	  vivo	  cleavage	  is	  therefore	  very	  difficult	  to	  realize	  in	  supernatants,	  where	  we	  cannot	  
optimize	  buffer	  conditions.	  Results	  showed	  that	  impurities	  present	  in	  the	  POMC	  conditioned	  medium	  
are	  sufficient	  to	  degrade	  the	  proopiomelanocortins,	  impeding	  any	  further	  analysis	  by	  PC-­‐2	  processing	  
(Fig.	  15).	  This	  experiment	  suggests	  that	  POMC	  purification	  is	  a	  pre-­‐requisite	  needed	  prior	  any	  further	  
analysis.	  	  
	  
Figure	  15.	  A.	  The	  membrane	  was	  loaded	  with	  Hu-­‐POMC	  incubated	  with	  or	  without	  PC-­‐2	  at	  t=0,	  t=6h,	  and	  t=96h	  and	  
revealed	  with	  antibody	  5-­‐MSH-­‐1G6-­‐1-­‐H1	  B.	  The	  same	  was	  done	  in	  this	  membrane	  but	  it	  was	  revealed	  with	  anti-­‐HA	  




E.	  IMMUNOPRECIPITATION	  OF	  POMC	  
Since	  our	  attempts	  of	  POMC	  purification	  using	  anti-­‐HA/anti-­‐V5	  
agarose	  beads	  were	  unsuccessful	  and	  given	  that	  this	  is	  a	  key	  step	  
required	  for	  our	  project,	  we	  decided	  to	  test	  an	  antibody	  directed	  
against	  the	  internal	  ACTH	  epitope,	  rather	  than	  N-­‐or	  C-­‐terminal	  
tags	  which	  might	  have	  been	  burried	  in	  natively	  folded	  POMC	  .	  In	  
order	  to	  purify	  SA-­‐POMC,	  we	  selected	  the	  antibody	  1-­‐ACTH-­‐1E3-­‐
4-­‐1,	  and	  anti-­‐HA	  as	  negative	  control,	  and	  coupled	  it	  to	  Protein	  A	  
Dynabeads.	  A	  third	  eppendorf	  tube	  contained	  no	  antibodies	  and	  
was	  used	  as	  negative	  control.	  	  Immunoprecipitation	  followed	  the	  
protocol	  described	  in	  materials	  and	  methods.	  
Immunoprecipitation	  of	  SA-­‐POMC	  using	  anti-­‐ACTH	  antibodies	  
coupled	  to	  the	  magnetic	  beads	  allowed	  us	  to	  successfully	  purify	  
the	  protein.	  In	  contrast,	  again	  the	  anti-­‐HA	  antibody	  was	  very	  
inefficient,	  further	  demonstrating	  that	  POMC	  cannot	  be	  purified	  
targeting	  N-­‐terminal	  tags	  (Fig.	  16).	  Despite	  the	  fact	  that	  POMC	  
was	  found	  to	  be	  a	  difficult	  protein	  to	  purify	  via	  terminal	  tags,	  we	  
identified	  the	  ACTH	  epitope	  as	  suitable	  for	  efficient	  pull-­‐down	  of	  
this	  protein.	  Further	  experiments	  are	  needed	  for	  protocol	  optimization.	  
	  
DISCUSSION	  AND	  PERSPECTIVES	  
POMC	  is	  the	  precursor	  of	  several	  hormones	  with	  a	  plethora	  of	  different	  functions.	  Understanding	  how	  
POMC	  is	  matured	  and	  investigating	  the	  mechanism	  behind	  the	  generation	  of	  the	  melanocortin	  products	  
is	  highly	  valuable	  to	  shed	  light	  into	  POMC	  biology	  in	  normal	  and	  pathological	  conditions.	  
Here,	  we	  produced	  and	  fully	  characterized	  recombinant	  forms	  of	  POMCs	  as	  well	  as	  the	  two	  enzymes	  –	  
PC-­‐1/3	  and	  PC-­‐2,	  known	  to	  be	  responsible	  for	  POMC	  cleavage	  into	  its	  active	  peptide	  hormones.	  In	  
addition,	  novel	  anti-­‐POMC	  antibodies	  have	  been	  tested	  and	  shown	  to	  be	  effective	  in	  ELISA	  and	  WB	  
analyses.	  
POMCs,	  PC-­‐1/3,	  and	  PC-­‐2	  supernatants	  were	  obtained	  by	  transient	  transfection	  in	  mammalian	  cells	  
using	  the	  EPFL	  platform	  for	  protein	  production.	  Proteins	  were	  produced	  at	  high	  levels	  and	  PC-­‐1/3	  and	  
	  
Figure	  16.	  Magnetic	  beads	  
immunoprecipitation.	  Dynabeads	  
magnetic	  beads	  were	  linked	  to	  
antibody	  1-­‐ACTH-­‐1E3-­‐4-­‐1,	  anti-­‐HA	  
antibody,	  and	  without	  antibodies.	  SA-­‐
POMC	  was	  loaded	  before	  and	  after	  
immunoprecipitation.	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PC-­‐2	  were	  highly	  active	  according	  to	  the	  expectations.	  	  Interestingly,	  we	  found	  that	  POMC	  per	  se	  at	  high	  
concentrations	  can	  activate	  PC-­‐1/3	  but	  not	  PC-­‐2.	  We	  can	  speculate	  that	  the	  substrate	  is	  able	  to	  dock	  to	  
the	  enzyme	  and	  to	  induce	  a	  conformational	  change	  favorable	  for	  activity.	  In	  this	  case,	  it	  is	  conceivable	  
that	  PC-­‐1/3	  activation	  can	  be	  regulated	  by	  the	  presence	  of	  the	  substrate,	  thus	  avoiding	  that	  the	  enzyme	  
cleaves	  wrong	  substrates.	  	  	  
We	  tried	  to	  purify	  POMC	  proteins	  by	  affinity	  purification,	  taking	  advantage	  on	  the	  C-­‐terminal	  or	  N-­‐
terminal	  tags	  (V5	  and	  HA).	  The	  two	  approaches	  did	  fail	  since	  we	  recovered	  the	  entire	  POMC	  in	  the	  
flowthrough.	  We	  hypothesize	  that	  the	  failure	  may	  be	  due	  to	  propensity	  of	  POMC	  to	  self-­‐associate	  to	  
form	  oligomers.	  This	  is	  in	  line	  with	  Cawley	  et	  al.	  [13].	  In	  this	  scenario,	  the	  terminal	  tags	  may	  be	  hindered	  
within	  the	  oligomeric	  structures.	  Further	  approaches	  may	  be	  successful	  to	  attain	  protein	  purification.	  
Using	  antibodies	  raised	  against	  central	  portion	  rather	  than	  C-­‐	  and	  N-­‐	  terminal	  of	  the	  protein	  could	  be	  a	  
better	  approach	  to	  purify	  POMC,	  as	  demonstrated	  by	  the	  magnetic	  beads	  affinity	  purification	  using	  
custom	  anti-­‐ACTH	  antibody	  1-­‐ACTH-­‐1E3-­‐4-­‐1.	  Indeed,	  previous	  studies	  on	  recombinant	  POMC	  showed	  
successful	  purification	  through	  affinity	  immunoprecipitation	  using	  anti	  γ-­‐MSH	  antibodies	  [14].	  Size	  
exclusion	  chromatography	  could	  be	  another	  option	  to	  purify	  POMC	  since	  this	  technique	  would	  separate	  
the	  different	  components	  of	  the	  solution	  based	  on	  their	  size.	  In	  other	  terms,	  no	  need	  of	  recognition	  of	  
specific	  epitopes	  by	  external	  antibodies	  is	  required.	  	  
The	  inability	  to	  purify	  large	  quantities	  of	  supernatant	  (very	  low	  amount	  of	  custom	  	  antibodies	  are	  
available)	  did	  impair	  the	  analysis	  of	  POMC	  processing	  since	  gross	  degradation	  does	  occur	  when	  POMC	  
supernatants	  are	  incubated	  at	  37°C	  with	  no	  extra	  addition	  of	  enzymes.	  Nonetheless,	  we	  decided	  to	  use	  
POMC	  supernatants	  in	  ELISA	  and	  WB,	  based	  on	  the	  low	  protein	  background	  observed	  in	  the	  Coomassie	  
gels.	  ELISA	  tests	  were	  performed	  to	  assess	  the	  specificity	  of	  an	  array	  of	  antibodies	  that	  were	  previously	  
raised.	  Among	  the	  several	  samples,	  we	  found	  antibodies	  capable	  to	  specifically	  recognize	  different	  parts	  
of	  POMC,	  including	  the	  three	  melanocortin	  stimulating	  hormones	  (MSH)	  α,	  β,	  and	  γ,	  with	  potential	  
applications	  in	  diagnostic	  as	  well	  as	  tools	  in	  biological	  tests.	  We	  are	  aware	  that	  the	  approach	  herein	  used	  
has	  limitations.	  Indeed,	  we	  will	  need	  to	  assess	  the	  response	  of	  the	  selected	  antibodies	  against	  
endogenous	  levels	  of	  POMC	  in	  ELISA	  tests.	  The	  sensitivity	  of	  our	  antibodies	  is	  extremely	  important,	  of	  
course,	  especially	  for	  medical	  applications.	  POMC	  detection	  in	  blood	  is	  currently	  used	  in	  order	  to	  
diagnose	  ectopic	  ACTH-­‐secreting	  tumors,	  and	  it	  is	  mainly	  detected	  through	  immunoradiometric	  assay.	  If	  
our	  antibodies	  are	  sensitive	  enough	  (high	  affinity	  binding),	  we	  may	  bypass	  the	  use	  of	  radioactive	  
material.	  Being	  able	  to	  detect	  POMC	  with	  ELISA	  without	  the	  use	  of	  a	  radioisotopic	  technique	  would	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reduce	  the	  cost	  of	  the	  diagnostic	  procedure	  and	  the	  impact	  of	  the	  radioactive	  markers	  to	  the	  users	  and	  
to	  the	  environment.	  
Surprisingly,	  we	  observed	  that	  many	  custom	  antibodies	  are	  reactive	  also	  in	  WB.	  So	  far,	  rare	  examples	  of	  
anti-­‐POMC	  antibodies	  have	  been	  reported	  with	  very	  low	  affinity.	  Thus,	  our	  antibodies	  represent	  a	  
valuable	  novel	  tool	  for	  POMC	  biology.	  Also	  in	  this	  case,	  the	  sensitivity	  of	  the	  antibody	  has	  to	  be	  
assessed.	  
Finally,	  the	  antibody	  library	  was	  useful	  to	  try	  to	  solve	  the	  problem	  of	  POMC	  purification.	  As	  proof-­‐of-­‐
concept,	  we	  showed	  that	  the	  anti-­‐POMC	  antibodies	  but	  not	  anti-­‐HA/V5	  can	  be	  used	  for	  affinity	  
purification	  of	  POMC.	  This	  is	  in	  line	  with	  our	  hypothesis	  that	  POMC	  oligomerizes,	  thus	  making	  only	  
specific	  parts	  of	  the	  protein	  accessible	  to	  the	  antibody.	  The	  large	  antibody	  database	  available	  could	  
provide	  a	  way	  to	  have	  a	  first	  insight	  of	  the	  conformational	  structure	  of	  the	  oligomers	  by	  testing	  if	  the	  
antibodies	  raised	  against	  different	  portion	  of	  POMC	  can	  bind	  to	  the	  oligomer.	  
Further	  application	  of	  antibodies	  raised	  against	  different	  hormones	  of	  the	  melanocortin	  system	  could	  
potentially	  be	  used	  diagnostically	  and	  therapeutically	  in	  order	  to	  prevent	  over	  stimulation	  of	  the	  
melanocortin	  receptors	  locally	  and	  remotely	  in	  cases	  of	  metastatic	  melanoma	  [15].	  Anti	  α-­‐MSH	  
antibodies,	  although	  not	  present	  in	  the	  antibody	  library,	  could	  be	  potentially	  useful	  in	  order	  to	  treat	  
anorexia	  nervosa	  by	  lowering	  the	  anorexigenic	  stimulation	  caused	  by	  α-­‐MSH	  on	  the	  MC4R.	  However,	  
this	  application	  is	  limited	  by	  the	  need	  of	  the	  antibody	  to	  cross	  the	  blood	  brain	  barrier	  [16].	  As	  said	  
earlier	  the	  detection	  of	  POMC	  through	  specific	  antibodies	  could	  help	  diagnose	  ectopic	  ACTH-­‐dependant	  
Cushing’s	  syndrome	  caused	  by	  an	  occult	  ectopic	  tumor	  that	  tends	  to	  elevate	  POMC	  plasma	  
concentration	  as	  opposed	  to	  pituitary	  secretion	  of	  ACTH	  that	  presents	  with	  lower	  plasma	  concentration	  
of	  POMC	  [17].	  
Overall,	  the	  studies	  here	  presented	  help	  in	  identifying	  novel	  anti-­‐POMC	  antibodies,	  working	  in	  ELISA	  and	  
WB	  analyses.	  We	  used	  them	  as	  tools	  to	  set	  a	  new	  protocol	  for	  POMC	  purification.	  Highly	  purified	  protein	  
will	  be	  extremely	  valuable	  for	  also	  the	  investigation	  of	  POMC	  processing	  and	  crystal	  structure.	  
	  
ACKNOWLEDGMENTS	  
First	  of	  all	  I	  would	  like	  to	  thank	  Professor	  Stefan	  Kunz	  for	  welcoming	  me	  in	  his	  team	  and	  for	  his	  
availability	  and	  teaching	  quality.	  I	  would	  also	  like	  to	  thank	  Doctor	  Karin	  Löw	  for	  providing	  me	  with	  
support	  and	  advice,	  as	  well	  as	  sharing	  expertise	  with	  me	  of	  the	  lab	  procedures	  I	  needed	  for	  this	  work.	  
My	  sincere	  thanks	  go	  to	  Doctor	  Antonella	  Pasquato	  for	  her	  guidance	  throughout	  the	  project	  and	  the	  
help	  with	  the	  realization	  of	  the	  protocols	  and	  the	  redaction	  of	  the	  thesis.	  
Adam	  J.	  Saint-­‐Roch	  
30	  
I	  would	  like	  to	  thank	  Anne-­‐Lyse	  Roulin	  for	  providing	  me	  with	  the	  custom	  antibodies	  and	  Alexandre	  
Roulin	  for	  being	  the	  expert	  of	  this	  project.	  
Lastly	  I	  would	  like	  to	  thank	  my	  lab	  mates	  who	  provided	  me	  with	  tips	  and	  a	  warm	  welcome.	  
	  
REFERENCES	  
1. Zhou	  A,	  Mains	  RE.	  Endoproteolytic	  processing	  of	  proopiomelanocortin	  and	  prohormone	  
convertases	  1	  and	  2	  in	  neuroendocrine	  cells	  overexpressing	  prohormone	  convertases	  1	  or	  2.	  J	  
Biol	  Chem,	  1994,	  17440	  
2. Furuta,	  M.	  et	  al.	  Severe	  defect	  in	  proglucagon	  processing	  in	  islet	  A-­‐cells	  of	  prohormone	  
convertase	  2	  null	  mice.	  J.	  Biol.	  Chem.	  276,	  27197–27202	  (2001)	  
3. Nabil	  G.	  Seidah,	  Mohamad	  Sayed	  Sadr,	  Michel	  Chretien,	  Majambu	  Mbikay;	  The	  multifaceted	  
proprotein	  convertases:	  their	  unique,	  redundant,	  complementary	  and	  opposite	  functions;	  J.	  Biol.	  
Chem	  published	  online	  June	  17,	  2013.	  
4. Zhou	  A.	  The	  prohormone	  convertases	  PC1	  and	  PC2	  mediate	  distinct	  endoproteolytic	  cleavages	  
in	  a	  strict	  temporal	  order	  during	  proopiomelanocortin	  biosynthetic	  processing.	  J	  Biol	  
Chem.	  1993	  Jan	  25;268(3):1763-­‐9.	  
5. Gantz	  I,	  Fong	  TM.	  The	  melanocortin	  system.	  Am	  J	  Physiol	  Endocrinol	  Metab.	  2003	  
Mar;284(3):E468-­‐74.	  
6. Judith	  Korner,	  M.D.,	  Ph.D.,	  and	  Rudolph	  L.	  Leibel,	  M.D.	  To	  Eat	  or	  Not	  to	  Eat	  —	  How	  the	  Gut	  Talks	  
to	  the	  Brain.	  N	  Engl	  J	  Med	  2003;	  349:926-­‐928	  
7. Mutch	  DM,	  Clément	  K.	  Unraveling	  the	  genetics	  of	  human	  obesity.	  PLoS	  Genet.	  2006	  Dec	  
29;2(12):e188.	  
8. Caruso	  V,	  Lagerström	  MC,	  Olszewski	  PK,	  Fredriksson	  R,	  Schiöth	  HB.	  Synaptic	  changes	  induced	  by	  
melanocortin	  signalling.	  Nat	  Rev	  Neurosci.	  2014	  Jan;15(2):98-­‐110.	  
9. Alexander	  SPH,	  Benson	  HE,	  Faccenda	  E,	  Pawson	  AJ,	  Sharman	  JL,	  Spedding	  M,	  Peters	  JA	  and	  
Harmar	  AJ,	  CGTP	  Collaborators.	  The	  Concise	  Guide	  to	  Pharmacology	  2013/14:	  G	  Protein-­‐
Coupled	  Receptors.	  Br	  J	  Pharmacol.	  170:	  1459–1581.	  
10. Dores	  RM	  et	  Al.	  Molecular	  evolution	  of	  GPCRs:	  Melanocortin/melanocortin	  receptors.	  J	  Mol	  
Endocrinol	  2014	  ;52	  :T29-­‐T42	  
11. Buono	  P,	  Pasanisi	  F,	  Nardelli	  C,	  Ieno	  L,	  Capone	  S,	  Liguori	  R,	  Finelli	  C,	  Oriani	  G,	  Contaldo	  
F,	  Sacchetti	  L.	  Six	  novel	  mutations	  in	  the	  proopiomelanocortin	  and	  melanocortin	  receptor	  4	  
genes	  in	  severely	  obese	  adults	  living	  in	  southern	  Italy.	  Clin	  Chem.	  2005	  Aug;51(8):1358-­‐64.	  
Epub	  2005	  Jun	  10.	  
12. Benjannet	  S,	  Rondeau	  N,	  Paquet	  L,	  Boudreault	  A,	  Lazure	  C,	  Chrétien	  M,	  Seidah	  NG.	  Comparative	  
biosynthesis,	  covalent	  post-­‐translational	  modifications	  and	  efficiency	  of	  prosegment	  cleavage	  of	  
the	  prohormone	  convertases	  PC1	  and	  PC2:	  glycosylation,	  sulphation	  and	  identification	  of	  the	  
intracellular	  site	  of	  prosegment	  cleavage	  of	  PC1	  and	  PC2.	  Biochem	  J.	  1993	  Sep	  15;294	  (Pt	  3):735	  
Adam	  J.	  Saint-­‐Roch	  
31	  
13. Cawley	  NX,	  Normant	  E,	  Chen	  A,	  Loh	  YP.	  Oligomerization	  of	  pro-­‐opiomelanocortin	  is	  independent	  
of	  pH,	  calcium	  and	  the	  sorting	  signal	  for	  the	  regulated	  secretory	  pathway.	  FEBS	  Lett.	  2000	  Sep	  
8;481(1):37-­‐41.	  
14. Rousseau	  K.	  et	  Al.	  Proopiomelanocortin	  (POMC),	  the	  ACTH/melanocortin	  precursor,	  is	  secreted	  
by	  human	  epidermal	  keratinocytes	  and	  melanocytes	  and	  stimulates	  melanogenesis.	  FASEB	  
J.	  2007	  Jun;21(8):1844-­‐56.	  	  
15. Suzuki	  I,	  Cone	  RD,	  Im	  S,	  Nordlund	  J,	  Abdel-­‐Malek	  ZA.	  Binding	  of	  melanotropic	  hormones	  to	  the	  
melanocortin	  receptor	  MC1R	  on	  human	  melanocytes	  stimulates	  proliferation	  and	  
melanogenesis.	  	  Endocrinology.	  1996	  May;137(5):1627-­‐33.	  
16. Hillebrand	   JJ,	   Kas	  MJ,	   Adan	   RA.	   alpha-­‐MSH	   enhances	   activity-­‐based	   anorexia.	   Peptides.	   2005	  
Oct;26(10):1690-­‐6.	  
17. Page-­‐Wilson	  G,	  Freda	  PU,	  Jacobs	  TP,	  Khandji	  AG,	  Bruce	  JN,	  Foo	  ST,	  Meece	  K,	  White	  A,	  Wardlaw	  
SL.	  Clinical	  utility	  of	  plasma	  POMC	  and	  AgRP	  measurements	  in	  the	  differential	  diagnosis	  of	  
ACTH-­‐dependent	  Cushing's	  syndrome.	  J	  Clin	  Endocrinol	  Metab.	  2014	  Oct;99(10):E1838-­‐45	  
